Semaglutide alleviates inflammation-Induced endothelial progenitor cells injury by inhibiting MiR-155 expression in macrophage exosomes

Pan, Xiaoyu; Yang, Lin; Wang, Shuqi; Liu, Qing; Yue, Lin; Chen, Shuchun

doi:10.1016/j.intimp.2023.110196

Cited by 11 publications

(5 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, there is a serious paucity of evidence regarding semaglutide, and most data derive from animal or in vitro studies. In endothelial progenitor cells, semaglutide inhibited lipopolysaccharide-induced macrophage expression of miR-155 in exosomes and improved cell viability and inflammatory status [ 17 ]. In ApoE-/- mice following vascular injury and blood flow perturbation, semaglutide reduced the intimal and medial area by ∼66% and ∼11%, respectively and reduced inflammatory markers [ 18 ], and this anti-inflammatory, antiproliferative effect on vascular remodeling has been observed with GLP-1RAs in previous in vitro studies with vascular smooth muscle cells [ 19 , 20 ].…”

Section: Discussionmentioning

confidence: 99%

Semaglutide Concurrently Improves Vascular and Liver Indices in Patients With Type 2 Diabetes and Fatty Liver Disease

Korakas,

Kountouri,

Pavlidis

et al. 2024

Journal of the Endocrine Society

View full text Add to dashboard Cite

Context The cardiovascular benefits of semaglutide are established; however, its effects on surrogate vascular markers and liver function are not known. Objective To investigate the effects of semaglutide on vascular, endothelial, and liver function in patients with type 2 diabetes (T2DM) and nonalcoholic fatty liver disease (NAFLD). Methods Overall, 75 consecutive subjects with T2DM and NAFLD were enrolled: 50 patients received semaglutide 1 mg (treatment group) and 25 patients received dipeptidyl peptidase 4 inhibitors (control group). All patients underwent a clinical, vascular, and hepatic examination with Fibroscan elastography at 4 and 12 months after inclusion in the study. Results Treatment with semaglutide resulted in a reduction of Controlled Attenuation Parameter (CAP) score, E fibrosis score, NAFLD fibrosis score, Fibrosis-4 (FIB-4) score and perfused boundary region (PBR) at 4 and at 12 months (P < .05), contrary to controls. Patients treated with semaglutide showed a greater decrease of central systolic blood pressure (SBP) (−6% vs −4%, P = .048 and −11% vs −9%, P = .039), augmentation index (AIx) (−59% vs −52%, P = .041 and −70% vs −57%, P = .022), and pulse wave velocity (PWV) (−6% vs −3.5%, P = .019 and −12% vs −10%, P = .036) at 4 and at 12 months, respectively. In all patients, ΔPWV and ΔPBR were correlated with a corresponding reduction of CAP, E fibrosis, NAFLD fibrosis, and FIB-4 scores. Conclusion Twelve-month treatment with semaglutide simultaneously improves arterial stiffness, endothelial function, and liver steatosis and fibrosis in patients with T2DM and NAFLD.

show abstract

Section: Discussionmentioning

confidence: 99%

Semaglutide Concurrently Improves Vascular and Liver Indices in Patients With Type 2 Diabetes and Fatty Liver Disease

Korakas,

Kountouri,

Pavlidis

et al. 2024

Journal of the Endocrine Society

View full text Add to dashboard Cite

show abstract

“…By encapsulating the desired drugs or expressing them on the membrane of exosomes, transfection is another commonly used endogenous drug-loading method to deliver monomeric compounds or nucleic acids into donor cells. 23 , 24 The transfection process can be achieved through chemical, electroporation, or virus vector-mediated arms, and the procedures are summarized as collecting donor cells, transfecting the required cargo into donor cells, collecting exosomes in the supernatant, removing cell debris and large molecular impurities, and finally harvesting drug-loaded exosomes. Practically, multiple factors must be considered when using the transfection method to load drugs, which includes the type of target cells, the properties of the required cargo drugs (such as size, charge, and hydrophilicity), and the desired therapeutic effects.…”

Section: Drug Loading Into Exosomes: Methods and Strategiesmentioning

confidence: 99%

Engineered Exosome for Drug Delivery: Recent Development and Clinical Applications

Tian,

Han,

Song

et al. 2023

IJN

View full text Add to dashboard Cite

Exosomes are nano-sized membrane vesicles that transfer bioactive molecules between cells and modulate various biological processes under physiological and pathological conditions. By applying bioengineering technologies, exosomes can be modified to express specific markers or carry therapeutic cargo and emerge as novel platforms for the treatment of cancer, neurological, cardiovascular, immune, and infectious diseases. However, there are many challenges and uncertainties in the clinical translation of exosomes. This review aims to provide an overview of the recent advances and challenges in the translation of engineered exosomes, with a special focus on the methods and strategies for loading drugs into exosomes, the pros and cons of different loading methods, and the optimization of exosome production based on the drugs to be encapsulated. Moreover, we also summarize the current clinical applications and prospects of engineered exosomes, as well as the potential risks and limitations that need to be addressed in exosome engineering, including the standardization of exosome preparation and engineering protocols, the quality and quantity of exosomes, the control of drug release, and the immunogenicity and cytotoxicity of exosomes. Overall, engineered exosomes represent an exciting frontier in nanomedicine, but they still face challenges in large-scale production, the maintenance of storage stability, and clinical translation. With continuous advances in this field, exosome-based drug formulation could offer great promise for the targeted treatment of human diseases.

show abstract

“…Recent studies have also shown that acute administration of exenatide can increase NO to maintain good diastolic function after reperfusion in isolated hearts ( Kadowaki et al, 2023 ). Furthermore, semaglutide can reduce lipopolysaccharides (LPS)-induced miR-155 secretion from macrophage exosomes to protect endothelial progenitor cell function ( Pan et al, 2023 ). These findings highlight the multifaceted beneficial effects of GLP-1RAs on the cardiovascular system.…”

Section: Cardiorenal Protection Of Sglt2i Glp-1ras and Dpp-4imentioning

confidence: 99%

Emerging role of antidiabetic drugs in cardiorenal protection

Fu,

Huo,

Mao

et al. 2024

Front. Pharmacol.

View full text Add to dashboard Cite

The global prevalence of diabetes mellitus (DM) has led to widespread multi-system damage, especially in cardiovascular and renal functions, heightening morbidity and mortality. Emerging antidiabetic drugs sodium-glucose cotransporter 2 inhibitors (SGLT2i), glucagon-like peptide-1 receptor agonists (GLP-1RAs), and dipeptidyl peptidase-4 inhibitors (DPP-4i) have demonstrated efficacy in preserving cardiac and renal function, both in type 2 diabetic and non-diabetic individuals. To understand the exact impact of these drugs on cardiorenal protection and underlying mechanisms, we conducted a comprehensive review of recent large-scale clinical trials and basic research focusing on SGLT2i, GLP-1RAs, and DPP-4i. Accumulating evidence highlights the diverse mechanisms including glucose-dependent and independent pathways, and revealing their potential cardiorenal protection in diabetic and non-diabetic cardiorenal disease. This review provides critical insights into the cardiorenal protective effects of SGLT2i, GLP-1RAs, and DPP-4i and underscores the importance of these medications in mitigating the progression of cardiovascular and renal complications, and their broader clinical implications beyond glycemic management.

show abstract

Semaglutide alleviates inflammation-Induced endothelial progenitor cells injury by inhibiting MiR-155 expression in macrophage exosomes

Cited by 11 publications

References 26 publications

Semaglutide Concurrently Improves Vascular and Liver Indices in Patients With Type 2 Diabetes and Fatty Liver Disease

Semaglutide Concurrently Improves Vascular and Liver Indices in Patients With Type 2 Diabetes and Fatty Liver Disease

Engineered Exosome for Drug Delivery: Recent Development and Clinical Applications

Emerging role of antidiabetic drugs in cardiorenal protection

Contact Info

Product

Resources

About